Topline results from a phase 3 study evaluating upadacitinib monotherapy in patients aged ≥12 years with moderate to severe atopic dermatitis (AD) showed the treatment was associated with significant improvement in skin clearance.
In the double-blind, placebo-controlled MEASURE UP 1 study, 847 patients aged ≥12 years with moderate to severe AD who are candidates for systemic therapy were randomized to receive upadacitinib 15mg (n=281) or 30mg (n=281) orally once daily, or placebo (n=285), followed by either upadacitinib 15mg or 30mg at week 16. The co-primary endpoints were the proportion of patients achieving at least a 75% improvement in the Eczema Area Severity Index (EASI 75) and a validated Investigator’s Global Assessment for Atopic Dermatitis (vIGA-AD) of clear or almost clear (0/1) at week 16.
Results showed 70% of patients treated with upadacitinib 15mg and 80% of patients treated with the 30mg dose achieved EASI 75 at week 16, compared with 16% in the placebo arm (P <.001). Additionally, 48% and 62% of patients treated with upadacitinib 15mg and 30mg, respectively, achieved vIGA-AD 0/1, respectively, compared with 8% in the placebo arm (P <.001).
Moreover, a significantly higher proportion of patients treated with upadacitinib had an improvement in Worst Pruritus Numerical Rating Scale ≥4 at week 16 (secondary end point) compared with placebo (52% with the 15mg dose and 60% with the 30mg dose vs 12% with placebo; P <.001). Patients also experienced clinically meaningful reductions in itch as early as day 2 in the 30mg arm (12% vs 4%; P <.001) and day 3 in the 15mg arm (16% vs 3%; P <.001) compared with placebo.
With regard to safety, there were no new safety risks observed with upadacitinib. The most common treatment-emergent adverse events were acne, upper respiratory tract infection and nasopharyngitis. Full study results will be presented at a future medical meeting and published in a peer-reviewed publication.
Upadacitinib, a selective and reversible Janus Kinase (JAK) inhibitor, is currently marketed under the brand name Rinvoq™ and is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate.
For more information visit abbvie.com.
This article originally appeared on MPR